First In Class potent cytototoxic and immune boosting small molecules against solid tumors (in vivo validated across 5 models)
The first generation of Imiqualines devloped by the team acted as anticancer agents with high cytotoxic activities on melanoma cell lines and in vivo on melanoma xenografts. The second generation of Imiqualines derivatives demonstrated higher activities than the first one with the Lead compound EAPB02303 presenting IC50 less than 15 nM on human melanoma and pancreatic cancer cell lines. EAPB02303 exhibits truly remarkable and highly contrasted activities on different cell lines.
The series were extensively studied and data available for EAPB02303 are PK parameters, MTD of single and repeated IP administration, hERG, in vivo activity : melanoma, breast, colorectal and pancreatic cancer, Proteomic – microarray analysis using A375-melanoma xenografts, Affinity chromatography for protein target search ...
AVAILABLE TECHNOLOGY | cancer – imiqualines